Early-Stage cancer drug trial halted after testing safety in small group
NCT ID NCT06056310
First seen Nov 01, 2025 · Last updated Apr 20, 2026 · Updated 22 times
Summary
This early-phase study tested whether adding an experimental drug called xevinapant to standard weekly chemotherapy and radiation was safe and tolerable for people with advanced head and neck cancer. It involved 18 participants with cancer that could not be removed by surgery. The main goal was to monitor for severe side effects, and the study was terminated early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Avera McKennan Hospital and University Health Center
Sioux Falls, South Dakota, 57105, United States
-
Centre Hospitalier de l'Ardenne - PARENT
Libramont, Belgium
-
China Medical University Hospital
Taichung, Taiwan
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Clinica Universidad de Navarra (MAD) - Oncology Service
Madrid, Spain
-
Hadassah University Hospital - Ein Kerem
Jerusalem, Israel
-
Hospital Universitario Fundacion Jimenez Diaz - Oncology
Madrid, Spain
-
Hospital Universitario Virgen del Rocio - Oncology Service
Seville, Spain
-
ICO Girona - Hospital Universitari de Girona Dr Josep Trueta - Servicio de Oncologia Medica
Girona, Spain
-
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan
-
Karmanos Cancer Institute - PARENT
Detroit, Michigan, 48201, United States
-
Konkuk University Medical Center
Seoul, South Korea
-
Montefiore Medical Center PRIME
The Bronx, New York, 10467, United States
-
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida, 33140, United States
-
National Taiwan University Hospital
Taipei, Taiwan
-
Pusan National University Hospital
Busan, South Korea
-
Pusan National University Yangsan Hospital
Yangsan, South Korea
-
Seoul National University Bundang Hospital
Seongnam, South Korea
-
Severance Hospital Yonsei University Health System
Seoul, South Korea
-
Taipei Veterans General Hospital
Taipei, Taiwan
-
Universitair Ziekenhuis Gent - Medical Oncology
Ghent, Belgium
-
Uza - Parent
Edegem, Belgium
-
Vitaz
Sint-Niklaas, Belgium
Conditions
Explore the condition pages connected to this study.